FMC’s Q1 profitability in the US was dampened by rising costs as reimbursements were up more moderately, but the other regions, especially EMEA and Asia-Pacific, lifted profitability, but not fully based on the business. Reported figures were not as strong as we had expected, but broadly met consensus. Despite the confirmation of guidance, management failed to include all effects in the FY guidance, which makes it not easy to read.
02 May 2019
Non-business related effects drive profitability
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Non-business related effects drive profitability
Fresenius Medical Care AG (FME:WBO) | 0 0 0.7% | Mkt Cap: 26,769m
- Published:
02 May 2019 -
Author:
Martin Schnee -
Pages:
3
FMC’s Q1 profitability in the US was dampened by rising costs as reimbursements were up more moderately, but the other regions, especially EMEA and Asia-Pacific, lifted profitability, but not fully based on the business. Reported figures were not as strong as we had expected, but broadly met consensus. Despite the confirmation of guidance, management failed to include all effects in the FY guidance, which makes it not easy to read.